NHSx

NIHR | National Institute for Health Research

ACCELERATED ACCESS COLLABORATIVE

Artificial Intelligence in Health and Care Award

From Research to Adoption

Dan Bamford,
Deputy Director AI Award

ACCELERATED ACCESS COLLABORATIVE

The AAC is a unique partnership between patient groups, government bodies, industry and NHS bodies

We **work together** to **streamline the adoption of new innovations in healthcare:**

PARTNER ORGANISATIONS

The **AHSN** Network

Academy of Medical Royal Colleges

ABHI — HealthTech for Life

abpi — Bringing medicines to life

amrc — ASSOCIATION OF MEDICAL RESEARCH CHARITIES

BiA — UK BioIndustry Association

Medicines & Healthcare products Regulatory Agency

NICE National Institute for Health and Care Excellence

NIHR | National Institute for Health Research

National Voices

NHS Digital

NHS

NHS x

BIVDA

HM Government

UKRI UK Research and Innovation

BOARD*

Lord Darzi

Amanda Pritchard

Matt Whitty

Prof. Gill Leng

Prof. Chris Whitty

Dr Louise Wood

Selected AAC Board Members

AIMS OF THE AWARD

£140m fund within AI Lab to establish the UK as the preeminent destination for developing and scaling health and care AI

1. Fund leading AI innovators to develop their technologies in UK

2. Build a world-class real-world AI testing infrastructure in UK

3. Accelerate adoption and spread of proven AI technologies across NHS

AI AWARD PHASES

Feasibility	Development & clinical evaluation	Real World Testing	Initial Health System Adoption	National Scale-up
Phase 1 AI Award NIHR	**Phase 2 AI Award NIHR**	**Phase 3 AI Award NHSX/AAC**	**Phase 4 AI Award NHSX/AAC**	**Phase 5 Not fundable**
To show product and clinical feasibility of the proposed concept, product or service	To develop prototypes and generate early clinical safety/efficacy data towards CE/UKCA marking	First real-world testing in health and social care settings to develop evidence of efficacy and preliminary proof of effectiveness, including evidence for routes to implementation to enable more rapid adoption	To facilitate initial systems adoption of the AI technologies with market authorisation into the NHS, evaluating the AI technology within clinical or operational pathways to determine efficacy or accuracy, and clinical and economic impact	To address barriers to adoption into routine care for NICE-approved products with proven health system benefits, in order to facilitate rapid uptake nationally
6-12 months Up to £150k	12-36 months Funding uncapped but typically range £500k-1.5m	12-36 months Funding uncapped but typically range £500k-1.5m	12-36 months Funding uncapped but typically range £1m - 7m	Not eligible for research and development funding under this programme

Overview of Round 1 Phase 4 Sites

Scotland
Brainomix: 1 site
RITA: 1 site
Veye: 1 site

North East and North Cumbria
Kheiron: 1 site
Echo: 1 site
Zio: 1 site

Innovation Agency AHSN
Mirada: 1 site
Echo: 1 site
Zio: 1 site
Veye: 1 site

Health Innovation Manchester
Echo: 1 site
Mirada: 1 site
Zio: 1 site
Optos: 2 site

Yorkshire and Humber AHSN
Healthyio: 1 site

East Midlands AHSN
DrDoctor: 1 site
RITA: 1 site
Zio: 1 site

Eastern AHSN
Echo: 1 site
Zio: 1 site
Optos: 1 site

West Midlands AHSN
RITA: 1 site
Zio: 1 site
DrDoctor: 1 site

UCL Partners
Kheiron: 1 site
Brainomix: 1 site
DrDoctor: 1 site
Healthyio: 1 site
Optos: 1 site

West of England AHSN
Kheiron: 1 site
Echo: 1 site
Zio: 2 site
Optos: 1 site

Wales
Kheiron: 1 site

Imperial College Health Partners
Optos: 1 site
Kheiron: 1 site
DrDoctor: 2 sites
Zio: 2 site

South West AHSN
Kheiron: 1 site
Brainomix: 1 site
Optos: 1 site

Wessex AHSN
Zio: 1 site
Healthyio: 1 site
Optos: 2 site
Veye: 1 site

Oxford AHSN
Brainomix: 1 site
Healthyio: 2 site
Echo: 2 site
DrDoctor: 1 site
Mirada: 1 site
Optos: 1 site

Kent Surrey Sussex AHSN
Brainomix: 1 site
RITA: 1 site
Healthyio: 1 site
Mirada: 1 site
Optos: 1 site

Health Innovation Network
DrDoctor: 1 site
Echo: 1 site
Zio: 4 site
Veye: 1 site

For live updates see AAC website map

England	66 sites
DA	4 sites

ROLE OF EVALUATION

We commission **independent evaluations** of the late-stage (P4) Award winners whilst they are being deployed in **real-world settings** aligned to key evidence gaps across eight domains:

Accuracy	Safety
Effectiveness	Value
Fit with site	Implementation
Feasibility of scale up	Sustainability of scale up

These evaluations serve to:

- Fill evidence gaps and accelerate local adoption and national adoption (via NICE guidance or UK NSC endorsement)

- Provide a model for late-stage, real-world evaluation of AI and generate learnings on the challenges and associated solutions.

More information on the AI Lab and AI in Health and Care Award

NHS x

www.nhsx.nhs.uk/ai-lab/

NIHR | National Institute for Health Research

enquiries@ai-award.info

www.nihr.ac.uk/explore-nihr/funding-programmes/ai-award.htm

ACCELERATED ACCESS COLLABORATIVE

www.england.nhs.uk/ai-award/